Naturally Occurring CRISPR/Cas9 Cuts DNA and RNA
By LabMedica International staff writers Posted on 12 Mar 2018 |
Image: CRISPR/Cas9 is a reprogrammable DNA cutting machine that is being used to edit genomes in many organisms for research purposes (Photo courtesy of Advanced Analytical Technologies).
A team of molecular microbiologists has identified a naturally occurring version of the CRISPR/Cas9 gene-editing complex that cuts both DNA and RNA with equal proficiency.
CRISPR/Cas9 is regarded as the cutting edge of molecular biology technology. CRISPRs (clustered regularly interspaced short palindromic repeats) are segments of prokaryotic DNA containing short repetitions of base sequences. Each repetition is followed by short segments of "spacer DNA" from previous exposures to a bacterial virus or plasmid. Since 2013, the CRISPR/Cas9 system has been used in research for gene editing (adding, disrupting, or changing the sequence of specific genes) and gene regulation. By delivering the Cas9 enzyme and appropriate guide RNAs (sgRNAs) into a cell, the organism's genome can be cut at any desired location. The conventional CRISPR/Cas9 system is composed of two parts: the Cas9 enzyme, which cleaves the DNA molecule and specific RNA guides that shepherd the Cas9 protein to the target gene on a DNA strand.
While recent work has shown that some Cas9 nucleases can also target RNA, RNA recognition has required nuclease modifications or accessory factors. Nonetheless, in a study published in the March 1, 2018, issue of the journal Molecular Cell investigators at the University of Würzburg (Germany) reported that the Campylobacter jejuni Cas9 (CjCas9) could bind and cleave complementary endogenous mRNAs.
"We continue to be amazed by what Cas9 is capable of doing and what new applications and technologies these insights create," said senior author Dr. Cynthia Sharma, professor of molecular infection biology at the University of Würzburg. "The protein is also capable of cutting related molecules, called ribonucleic acids - RNA, for short. Not only that, but we found that we could also program this Cas9 to target and cut specific RNA molecules."
Related Links:
University of Würzburg
CRISPR/Cas9 is regarded as the cutting edge of molecular biology technology. CRISPRs (clustered regularly interspaced short palindromic repeats) are segments of prokaryotic DNA containing short repetitions of base sequences. Each repetition is followed by short segments of "spacer DNA" from previous exposures to a bacterial virus or plasmid. Since 2013, the CRISPR/Cas9 system has been used in research for gene editing (adding, disrupting, or changing the sequence of specific genes) and gene regulation. By delivering the Cas9 enzyme and appropriate guide RNAs (sgRNAs) into a cell, the organism's genome can be cut at any desired location. The conventional CRISPR/Cas9 system is composed of two parts: the Cas9 enzyme, which cleaves the DNA molecule and specific RNA guides that shepherd the Cas9 protein to the target gene on a DNA strand.
While recent work has shown that some Cas9 nucleases can also target RNA, RNA recognition has required nuclease modifications or accessory factors. Nonetheless, in a study published in the March 1, 2018, issue of the journal Molecular Cell investigators at the University of Würzburg (Germany) reported that the Campylobacter jejuni Cas9 (CjCas9) could bind and cleave complementary endogenous mRNAs.
"We continue to be amazed by what Cas9 is capable of doing and what new applications and technologies these insights create," said senior author Dr. Cynthia Sharma, professor of molecular infection biology at the University of Würzburg. "The protein is also capable of cutting related molecules, called ribonucleic acids - RNA, for short. Not only that, but we found that we could also program this Cas9 to target and cut specific RNA molecules."
Related Links:
University of Würzburg
Latest BioResearch News
- Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns
- Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma
- New Method Simplifies Preparation of Tumor Genomic DNA Libraries
- New Tool Developed for Diagnosis of Chronic HBV Infection
- Panel of Genetic Loci Accurately Predicts Risk of Developing Gout
- Disrupted TGFB Signaling Linked to Increased Cancer-Related Bacteria
- Gene Fusion Protein Proposed as Prostate Cancer Biomarker
- NIV Test to Diagnose and Monitor Vascular Complications in Diabetes
- Semen Exosome MicroRNA Proves Biomarker for Prostate Cancer
- Genetic Loci Link Plasma Lipid Levels to CVD Risk
- Newly Identified Gene Network Aids in Early Diagnosis of Autism Spectrum Disorder
- Link Confirmed between Living in Poverty and Developing Diseases
- Genomic Study Identifies Kidney Disease Loci in Type I Diabetes Patients
- Liquid Biopsy More Effective for Analyzing Tumor Drug Resistance Mutations
- New Liquid Biopsy Assay Reveals Host-Pathogen Interactions
- Method Developed for Enriching Trophoblast Population in Samples